Simtuzumab

DB12152InvestigationalProtein Based Therapies

Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.

Mechanism: Pharmacologically active on Lysyl oxidase homolog 2
Curator reviewed
Also known as: GS-6624 · Recombinant humanized anti-LOXL2 monoclonal antibody

Resolves to

Compound

UNII11Z5AIU653CAS1318075-13-6

Targets

Q9Y4K0LOXL2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Simtuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account